On Friday, Aquestive Therapeutics, Inc. (NASDAQ:AQST) hosted a virtual investor day highlighting the company’s Anaphylm ...

Cambridge, Massachusetts-based biotech Regor Therapeutics Group has agreed to sell its portfolio of CDK inhibitors for the treatment of breast cancer to Roche's Genentech for an upfront cash payment ...

In a report released on September 28, Louise Chen from Cantor Fitzgerald maintained a Buy rating on Johnson & Johnson (JNJ – ...

The Swiss pharma is paying Regor Therapeutics $850 million to buy a pair of prospects it sees as potential successors to blockbuster medicines from Pfizer and Eli Lilly.

Here, Hancock cites fund holding Eli Lilly and its patents on GLP-1 weight loss drugs Mounjaro and Zepbound. Hancock expects ...

Roche (OTCQX:RHHBY) said Monday that three obesity and diabetes drug candidates acquired through its takeover of Carmot ...

Analyst Chris Schott from J.P. Morgan maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) and keeping the price target ...

With the third quarter of 2024 ending, the discourse on the stock market for global equities has shifted back to interest ...

Healthcare is always a hot button topic discussed during election years. This election cycle is no different, especially for ...

Eli Lilly's Ebglyss gains FDA approval for atopic dermatitis treatment, poised to rival Dupixent with strong performance in ...

Roche said on Monday that three early-stage obesity and diabetes drug candidates from its acquisition of Carmot Therapeutics ...

Having banked $60 million from Eli Lilly in the spring, Aktis Oncology has now closed an upsized $175 million series B that ...